Corallopyronin A as antifilarial drug - A natural antibiotic product for the effective treatment of dirofilariasis
Ref.-No. 2838 - Veterinary
Keywords: heartworm (Wolbachia), dirofilariosis, dog, anthelmintic (anti-worm), anti-filarial, DZIF (Deutsches Zentrum für Infektionsforschung)
Canine dirofilariasis, commonly known as heartworm disease, is caused by the nematode parasites Dirofilaria immitis and D. repens and transmitted through mosquito bites into dogs. The parasites inhabits the heart and pulmonary arteries, causing damage to these organs. Wolbachia, the bacterial endosymbiont of the parasites, crucially regulate the nematodes’ life cycle. Standard treatment for dirofilariasis involves ivermectin prophylactically or melarsomine on the therapeutic level. However, these drugs are known to cause side effects and resistance.
Corallopyronin A (CorA) is a novel non-competitive inhibitor of the bacterial DNA-dependent RNA polymerase. CorA aims at slowly killing Wolbachia, thus avoiding strong inflammatory reactions. The IP package further comprises a production process of CorA, established on a 15,000 litre scale in preparation for GMP manufacturing, and a stable formulation for oral administration.
Competitive Advantages
- Effective treatment of canine dirofilariasis
- Slow worm death prevents potential endotoxic shock
- Oral administration of CorA
- Stable formulation of CorA
Commercial Opportunities
On behalf of the University of Bonn, PROvendis offers an access to rights for commercial use (patent applications, patents and know-how).
Current Status
Assessment CorA | Results |
Production and formulation
|
Each up to 15,000 L 35 to 90 g batches Gastro resistant capsules for oral application |
Toxicology (non-GLP)
|
EC50 [µM]: A3= 11, PPARγ= 2.2, COX1= 8.2 No inhibiton of six recombinant human CYPs EC50 [µM]: 12 1000 mg/kg; moderate, transient symptoms 0, 150, 450, 750 mg/kg bw/day 150 mg/kg bw/day: NOAEL (preliminary) Cmax 208 µg/ml (d1) / 212 µg/ml (d7) |
Safety Pharmacology
|
2024 Radiotelemetry, 2024 Q4/2023 - Q2/2024 |
Technology Readiness Level
1
2
3
4
5
6
7
8
9
Technology validated in relevant environment
Relevant Puclications
More information on IP status on request.
Becker T. et.al Eur J Pharm Biopharm (2023); Rox et al., Pharmaceutics. 2023; 15(1):131;
Ehrens et al., Front. Trop. Dis., Vol. 3 (2022); Krome et al., Nat Prod Rep 39:1705-1720;
Krome et al., Pharmaceutics 12 (2020):1105; Becker et al. Pharmaceutics (2022) 14:1657
—
An invention of the University of Bonn.
Dipl.-Biol. Kordula Kruber
kk@provendis.info
+49 208 9410530